Research Updates

Back to feed
PubMed
Single case report

High importance

Oct 7, 2026

From Refractory Iron Deficiency Anemia to the Diagnosis of Hereditary Hemorrhagic Telangiectasia Type 1: A Case Report.

View original source

Why it matters

This case illustrates how important it is to consider HHT in patients with unexplained anemia and bleeding. It also suggests that new treatments like bevacizumab might help patients who suffer from severe bleeding related to HHT, but more research is needed.

Objective

This case report aims to highlight the diagnosis of Hereditary Hemorrhagic Telangiectasia (HHT) in a patient with a long history of iron deficiency anemia and recurrent bleeding.

Results

The patient showed significant improvement after treatment, including better hemoglobin levels and reduced bleeding. Genetic testing confirmed the diagnosis of HHT type 1.

Methods

This is a case study of a 70-year-old man with chronic anemia who underwent various examinations including genetic testing, endoscopy, and imaging to identify vascular issues associated with HHT. The patient received treatment for bleeding lesions and systemic therapy.

Limitations

This is a single case report, which means it reflects one patient’s experience and may not apply to everyone with HHT. Further studies are needed to better understand the effectiveness of treatments like bevacizumab in different cases.

For your doctor:

PMID: 42999694

DOI: 10.7759/cureus.117613

Abstract

Hereditary hemorrhagic telangiectasia (HHT) is an autosomal-dominant vascular disorder characterized by mucocutaneous telangiectasias and visceral arteriovenous malformations (AVMs) resulting in recurrent epistaxis, gastrointestinal bleeding, iron deficiency anemia, and complications related to pulmonary and cerebral vascular shunting. We report the case of a 70-year-old man with a 20-year history of refractory iron deficiency anemia requiring frequent blood transfusions and intravenous iron therapy who presented with recurrent epistaxis, melena, exertional dyspnea, and bilateral lower-limb edema. Examination demonstrated multiple telangiectasias involving the fingertips, nasal mucosa, oral cavity, and tongue. Endoscopic evaluation revealed multiple bleeding telangiectatic lesions involving the stomach, jejunum, and colon, with argon plasma coagulation performed for hemostasis. Contrast-enhanced computed tomography demonstrated multisystem AVMs involving the lungs, liver, and spleen, while no cerebral AVM was identified. Contrast echocardiography demonstrated a delayed appearance of microbubbles in the left atrium after five cardiac cycles, consistent with an intrapulmonary shunt. Genetic testing identified a pathogenic variant in the endoglin (ENG) gene, confirming HHT type 1. A significant pulmonary arteriovenous malformation was treated with transcatheter embolization. In view of severe recurrent bleeding and transfusion-dependent anemia despite local measures, systemic bevacizumab was initiated at 5 mg/kg every two weeks for six doses, followed by monthly maintenance therapy. The patient subsequently demonstrated a marked clinical response, with improvement in hemoglobin levels and cessation of melena, without an infusion-related adverse reaction. This case highlights the importance of recognizing HHT in patients with longstanding unexplained iron deficiency anemia and recurrent bleeding from multiple vascular territories and demonstrates the potential role of systemic bevacizumab in patients with severe HHT-associated bleeding.